We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.62%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.43B
AUM Growth
+$108M
Cap. Flow
-$133M
Cap. Flow %
-9.27%
Top 10 Hldgs %
45.41%
Holding
87
New
7
Increased
18
Reduced
17
Closed
14

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$37.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$31.2M
3
ACLX
Arcellx
ACLX
+$29.2M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$22.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.3M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$187M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$35.3M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
51
Olema Pharmaceuticals
OLMA
$1.05B
$5.75M 0.4%
2,082,000
– –
VIGL
52
DELISTED
Vigil Neuroscience
VIGL
$5.61M 0.39%
616,786
– –
ASND icon
53
Ascendis Pharma A/S
ASND
$16.8B
$5.16M 0.36%
50,000
– –
KROS icon
54
Keros Therapeutics
KROS
$221M
$3.76M 0.26%
100,000
– –
ELDN icon
55
Eledon Pharmaceuticals
ELDN
$285M
$3.38M 0.24%
1,223,500
-81,595
-6% -$260K
AKUS
56
DELISTED
Akouos Inc
AKUS
$2.67M 0.19%
394,500
– –
AMAM
57
DELISTED
Ambrx Biopharma Inc
AMAM
$2.52M 0.18%
2,336,389
-149,997
-6% -$309K
TRML
58
DELISTED
Tourmaline Bio
TRML
$2.37M 0.17%
90,065
-27,407
-23% -$998K
ELEV
59
DELISTED
Elevation Oncology
ELEV
$2.21M 0.15%
1,952,032
-31,136
-2% -$39.2K
YMAB
60
DELISTED
Y-mAbs Therapeutics
YMAB
$2.16M 0.15%
150,000
– –
ICVX
61
DELISTED
Icosavax, Inc. Common Stock
ICVX
$2.03M 0.14%
643,825
-7,568
-1% -$47.3K
DMRA
62
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.93M 0.13%
40,810
– –
XFOR icon
63
X4 Pharmaceuticals
XFOR
$460M
$1.42M 0.1%
27,688
+24,222
+699% +$837K
PYXS icon
64
Pyxis Oncology
PYXS
$236M
$1.32M 0.09%
668,855
+1
+0% +$3
AUTL
65
Autolus Therapeutics
AUTL
$562M
$839K 0.06%
392,167
– –
CABA icon
66
Cabaletta Bio
CABA
$455M
$750K 0.05%
1,154,424
– –
CMMB
67
Chemomab Therapeutics
CMMB
$14.1M
$718K 0.05%
72,042
– –
GLS
68
DELISTED
Gelesis Holdings, Inc.
GLS
$676K 0.05%
626,107
-1
-0% -$1
LENZ
69
LENZ Therapeutics
LENZ
$168M
$633K 0.04%
28,507
– –
HARP
70
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$524K 0.04%
54,060
– –
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$501K 0.04%
319,057
– –
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$128K 0.01%
25,665
– –
IMV
73
DELISTED
IMV Inc. Common Shares
IMV
$122K 0.01%
23,437
– –
AKRO
74
DELISTED
Akero Therapeutics
AKRO
– –
-403,787
Closed -$3.82M
ANAB icon
75
AnaptysBio
ANAB
$1.68B
– –
-50,000
Closed -$1.01M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Cormorant Asset Management held 87 positions worth $1.43B, up 8.2% from $1.32B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $133M in Q3 2022, closing 14 positions and reducing 17 holdings. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $187M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Arcutis Biotherapeutics worth $19.1M.

  • Cormorant Asset Management's largest Q3 2022 buy was Arcutis Biotherapeutics: 1,000,000 shares worth $19.1M.
  • Cormorant Asset Management added most to Gossamer Bio in Q3 2022, an estimated $37.2M increase.
  • Cormorant Asset Management's biggest Q3 2022 reduction was Design Therapeutics, cutting an estimated $9.95M.
  • Cormorant Asset Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $187M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.43B portfolio in Q3 2022.
  • Cormorant Asset Management opened 7 new positions and closed 14 in Q3 2022.
  • Cormorant Asset Management's portfolio value rose 8.2% quarter-over-quarter to $1.43B.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.